Clinical trials: Experimental
Hepatic Insufficiency, Healthy
Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety after single oral administration of FYU-981 to subjects with hepatic insufficiency and with normal hepatic function.
- Trial name
- NCT03306667
- Testing
- FYU-981
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Healthy
Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers (II)
This is a randomized, open-label, single dose study to evaluate the safety and pharmacokinetics of DWP14012 tablet A and DWP14012 tablet B in healthy volunteers
- Trial name
- NCT04167267
- Testing
- DWP14012 tablet A, DWP14012 tablet B
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Gingivitis
Evaluation of the Addition of an Interdental Cleaning Device to Manual Brushing on Gingival Health
This study evaluates the addition of an interdental cleaning device paired with a manual toothbrush compared to using a manual toothbrush only. Plaque removal, reduction of gingival bleeding and reduction of gingival inflammation.
- Trial name
- NCT02836223
- Testing
- Interdental cleaning device, Manual Tooth brush
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Water Pik, Inc.
Neoplasms, Hematologic
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with…
- Trial name
- NCT01594723
- Testing
- 120 mg LY2784544
- Where
- 39 sites in United States, Australia and 7 more
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company
Chronic Myelogenous Leukemia - Chronic Phase
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
This study was a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP harboring the T315I mutation with at least 1 prior…
- Trial name
- AIM4CML (NCT04666259)
- Testing
- ABL001
- Where
- 26 sites in United States
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis (RA)
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis…
- Trial name
- NCT03660059
- Testing
- Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 385 people
- Sponsor
- Astellas Pharma China, Inc.
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion…
- Trial name
- NCT07084896
- Testing
- Belantamab mafodotin, Nirogacestat
- Where
- 29 sites in United States, Australia and 11 more
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Healthy
Proellex® Pharmacokinetic Bridging Study II
An open-label, randomized, single-center, outpatient, unblinded, single-dose, three-way crossover study of the safety and PK properties of Proellex® in women ages 18 - 34 years.
- Trial name
- PK (NCT00620503)
- Testing
- Proellex 25 mg formulation A, Proellex 25 mg formulation B
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Narcolepsy Type 1
A Study of TAK-861 in Participants With Narcolepsy Type 1
The main aim of this study is to see how TAK-861 works on symptoms of narcolepsy, including excessive daytime sleepiness and cataplexy.
- Trial name
- NCT05687903
- Testing
- TAK-861
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 112 people
- Sponsor
- Takeda
Actinic Keratoses
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis
Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical…
- Trial name
- NCT05078827
- Testing
- Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
- Where
- 7 sites in United States
- Volunteers
- 458 people
- Sponsor
- Encube Ethicals Pvt. Ltd.
Venous Leg Ulcer, Chronic Wounds
Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers
This is a randomized controlled trial evaluating the efficacy of HYALOMATRIX in conjunction with standard of care vs. standard of care alone in treating venous leg ulcers.
- Trial name
- NCT07335861
- Testing
- Hyalomatrix, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- NuScience Medical Biologics, LLC
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Amyloidosis
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
- Trial name
- NCT02510261
- Testing
- Patisiran
- Where
- 56 sites in United States, Argentina and 19 more
- Volunteers
- 211 people
- Sponsor
- Alnylam Pharmaceuticals
Parkinson Disease, Movement Disorders
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
This study evaluates the safety and tolerability of CDNF in patients with Parkinson's disease, when dosed directly into the brain using an implanted investigational drug delivery system (DDS).
- Conditions
- Parkinson Disease, Movement Disorders, Neurodegenerative Diseases, Nervous System Diseases
- Trial name
- NCT03295786
- Testing
- Cerebral Dopamine Neurotrophic Factor, Renishaw Drug Delivery System
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 17 people
- Sponsor
- Herantis Pharma Plc.
Healthy
A Phase 1 Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers
The purpose of this phase1 study is to investigate the pharmacokinetics, safety and tolerability of a single oral dose of SA001 and its active metabolite in healthy male volunteers.
- Trial name
- NCT02470286
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Urinary Incontinence
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
- Trial name
- NCT00127270
- Testing
- Darifenacin, Behavioral therapy
- Where
- 67 sites in United States
- Volunteers
- 395 people
- Sponsor
- Novartis
Dry Eye Disease
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating…
- Trial name
- RELIEF (NCT05896670)
- Testing
- licaminlimab, vehicle of OCS-02, Artificial tears
- Where
- 5 sites in United States
- Volunteers
- 122 people
- Sponsor
- Oculis
Gastrointestinal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an…
- Trial name
- REJOICE-GI01 (NCT06864169)
- Testing
- Raludotatug Deruxtecan (R-DXd)
- Where
- 41 sites in United States, Argentina and 8 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor and Lymphoma
A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma
The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the…
- Trial name
- NCT07333469
- Testing
- HX111 for injection
- Volunteers
- 70 people
- Sponsor
- Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.